Name: | Description: | Size: | Format: | |
---|---|---|---|---|
851.41 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Xanthones have been suggested as prospective candidates for cancer treatment. 1,2-
dihydroxyxanthone (1,2-DHX) is known to interfere with the growth of several cancer cell lines. We
investigated the effects of 1,2-DHX on the growth of the A375-C5 melanoma cell line and THP-1 human
macrophage activity. 1,2-DHX showed a moderate growth inhibition of A375-C5 melanoma cells
(concentration that causes a 50% inhibition of cell growth (GI50) = 55.0 ±2.3 µM), but strongly interfered
with THP-1 human macrophage activity. Supernatants from lipopolysaccharide (LPS)-stimulated
THP-1 macrophage cultures exposed to 1,2-DHX significantly increased growth inhibition of A375-C5
cells, when compared to supernatants from untreated LPS-stimulated macrophages or to direct
treatment with 1,2-DHX only. 1,2-DHX decreased THP-1 secretion of interleukin-1β (IL-1β) and
interleukin-10 (IL-10), but stimulated tumor necrosis factor-α (TNF-α) and transforming growth
factor-β1 (TGF-β1) production. This xanthone also inhibited nitric oxide (NO) production by RAW
264.7 murine macrophages, possibly through inhibition of inducible NO synthase production. In
conclusion, these findings suggest a potential impact of 1,2-DHX in melanoma treatment, not only
due to a direct effect on cancer cells but also by modulation of macrophage activity.
Description
Keywords
Xanthones Melanoma Macrophages Cytokines
Citation
Publisher
MDPI